Cargando…

Inexpensive, non-invasive biomarkers predict Alzheimer transition using machine learning analysis of the Alzheimer’s Disease Neuroimaging (ADNI) database

The Alzheimer’s Disease Neuroimaging (ADNI) database is an expansive undertaking by government, academia, and industry to pool resources and data on subjects at various stage of symptomatic severity due to Alzheimer’s disease. As expected, magnetic resonance imaging is a major component of the proje...

Descripción completa

Detalles Bibliográficos
Autores principales: Beltrán, Juan Felipe, Wahba, Brandon Malik, Hose, Nicole, Shasha, Dennis, Kline, Richard P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384664/
https://www.ncbi.nlm.nih.gov/pubmed/32716914
http://dx.doi.org/10.1371/journal.pone.0235663
_version_ 1783563644846473216
author Beltrán, Juan Felipe
Wahba, Brandon Malik
Hose, Nicole
Shasha, Dennis
Kline, Richard P.
author_facet Beltrán, Juan Felipe
Wahba, Brandon Malik
Hose, Nicole
Shasha, Dennis
Kline, Richard P.
author_sort Beltrán, Juan Felipe
collection PubMed
description The Alzheimer’s Disease Neuroimaging (ADNI) database is an expansive undertaking by government, academia, and industry to pool resources and data on subjects at various stage of symptomatic severity due to Alzheimer’s disease. As expected, magnetic resonance imaging is a major component of the project. Full brain images are obtained at every 6-month visit. A range of cognitive tests studying executive function and memory are employed less frequently. Two blood draws (baseline, 6 months) provide samples to measure concentrations of approximately 145 plasma biomarkers. In addition, other diagnostic measurements are performed including PET imaging, cerebral spinal fluid measurements of amyloid-beta and tau peptides, as well as genetic tests, demographics, and vital signs. ADNI data is available upon review of an application. There have been numerous reports of how various processes evolve during AD progression, including alterations in metabolic and neuroendocrine activity, cell survival, and cognitive behavior. Lacking an analytic model at the onset, we leveraged recent advances in machine learning, which allow us to deal with large, non-linear systems with many variables. Of particular note was examining how well binary predictions of future disease states could be learned from simple, non-invasive measurements like those dependent on blood samples. Such measurements make relatively little demands on the time and effort of medical staff or patient. We report findings with recall/precision/area under the receiver operator curve after application of CART, Random Forest, Gradient Boosting, and Support Vector Machines, Our results show (i) Random Forests and Gradient Boosting work very well with such data, (ii) Prediction quality when applied to relatively easily obtained measurements (Cognitive scores, Genetic Risk and plasma biomarkers) achieve results that are competitive with magnetic resonance techniques. This is by no means an exhaustive study, but instead an exploration of the plausibility of defining a series of relatively inexpensive, broad population based tests.
format Online
Article
Text
id pubmed-7384664
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-73846642020-08-05 Inexpensive, non-invasive biomarkers predict Alzheimer transition using machine learning analysis of the Alzheimer’s Disease Neuroimaging (ADNI) database Beltrán, Juan Felipe Wahba, Brandon Malik Hose, Nicole Shasha, Dennis Kline, Richard P. PLoS One Research Article The Alzheimer’s Disease Neuroimaging (ADNI) database is an expansive undertaking by government, academia, and industry to pool resources and data on subjects at various stage of symptomatic severity due to Alzheimer’s disease. As expected, magnetic resonance imaging is a major component of the project. Full brain images are obtained at every 6-month visit. A range of cognitive tests studying executive function and memory are employed less frequently. Two blood draws (baseline, 6 months) provide samples to measure concentrations of approximately 145 plasma biomarkers. In addition, other diagnostic measurements are performed including PET imaging, cerebral spinal fluid measurements of amyloid-beta and tau peptides, as well as genetic tests, demographics, and vital signs. ADNI data is available upon review of an application. There have been numerous reports of how various processes evolve during AD progression, including alterations in metabolic and neuroendocrine activity, cell survival, and cognitive behavior. Lacking an analytic model at the onset, we leveraged recent advances in machine learning, which allow us to deal with large, non-linear systems with many variables. Of particular note was examining how well binary predictions of future disease states could be learned from simple, non-invasive measurements like those dependent on blood samples. Such measurements make relatively little demands on the time and effort of medical staff or patient. We report findings with recall/precision/area under the receiver operator curve after application of CART, Random Forest, Gradient Boosting, and Support Vector Machines, Our results show (i) Random Forests and Gradient Boosting work very well with such data, (ii) Prediction quality when applied to relatively easily obtained measurements (Cognitive scores, Genetic Risk and plasma biomarkers) achieve results that are competitive with magnetic resonance techniques. This is by no means an exhaustive study, but instead an exploration of the plausibility of defining a series of relatively inexpensive, broad population based tests. Public Library of Science 2020-07-27 /pmc/articles/PMC7384664/ /pubmed/32716914 http://dx.doi.org/10.1371/journal.pone.0235663 Text en © 2020 Beltrán et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Beltrán, Juan Felipe
Wahba, Brandon Malik
Hose, Nicole
Shasha, Dennis
Kline, Richard P.
Inexpensive, non-invasive biomarkers predict Alzheimer transition using machine learning analysis of the Alzheimer’s Disease Neuroimaging (ADNI) database
title Inexpensive, non-invasive biomarkers predict Alzheimer transition using machine learning analysis of the Alzheimer’s Disease Neuroimaging (ADNI) database
title_full Inexpensive, non-invasive biomarkers predict Alzheimer transition using machine learning analysis of the Alzheimer’s Disease Neuroimaging (ADNI) database
title_fullStr Inexpensive, non-invasive biomarkers predict Alzheimer transition using machine learning analysis of the Alzheimer’s Disease Neuroimaging (ADNI) database
title_full_unstemmed Inexpensive, non-invasive biomarkers predict Alzheimer transition using machine learning analysis of the Alzheimer’s Disease Neuroimaging (ADNI) database
title_short Inexpensive, non-invasive biomarkers predict Alzheimer transition using machine learning analysis of the Alzheimer’s Disease Neuroimaging (ADNI) database
title_sort inexpensive, non-invasive biomarkers predict alzheimer transition using machine learning analysis of the alzheimer’s disease neuroimaging (adni) database
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7384664/
https://www.ncbi.nlm.nih.gov/pubmed/32716914
http://dx.doi.org/10.1371/journal.pone.0235663
work_keys_str_mv AT beltranjuanfelipe inexpensivenoninvasivebiomarkerspredictalzheimertransitionusingmachinelearninganalysisofthealzheimersdiseaseneuroimagingadnidatabase
AT wahbabrandonmalik inexpensivenoninvasivebiomarkerspredictalzheimertransitionusingmachinelearninganalysisofthealzheimersdiseaseneuroimagingadnidatabase
AT hosenicole inexpensivenoninvasivebiomarkerspredictalzheimertransitionusingmachinelearninganalysisofthealzheimersdiseaseneuroimagingadnidatabase
AT shashadennis inexpensivenoninvasivebiomarkerspredictalzheimertransitionusingmachinelearninganalysisofthealzheimersdiseaseneuroimagingadnidatabase
AT klinerichardp inexpensivenoninvasivebiomarkerspredictalzheimertransitionusingmachinelearninganalysisofthealzheimersdiseaseneuroimagingadnidatabase
AT inexpensivenoninvasivebiomarkerspredictalzheimertransitionusingmachinelearninganalysisofthealzheimersdiseaseneuroimagingadnidatabase